Royce & Associates LP Acquires Shares of 114,968 Astrana Health, Inc. (NASDAQ:ASTH)

Royce & Associates LP purchased a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the third quarter, HoldingsChannel.com reports. The firm purchased 114,968 shares of the company’s stock, valued at approximately $6,661,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank acquired a new stake in shares of Astrana Health during the third quarter valued at about $713,000. Diamond Hill Capital Management Inc. acquired a new stake in Astrana Health during the 3rd quarter valued at approximately $8,245,000. Summit Global Investments purchased a new stake in Astrana Health during the 3rd quarter worth approximately $753,000. Louisiana State Employees Retirement System acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $1,165,000. Finally, F M Investments LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $11,738,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Wall Street Analyst Weigh In

ASTH has been the subject of a number of research analyst reports. TD Cowen initiated coverage on shares of Astrana Health in a research note on Monday, October 14th. They issued a “buy” rating and a $66.00 price target for the company. BTIG Research upped their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Stifel Nicolaus increased their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Truist Financial boosted their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Astrana Health has an average rating of “Buy” and a consensus price target of $65.17.

Astrana Health Stock Performance

Shares of NASDAQ ASTH opened at $40.81 on Monday. The stock has a market capitalization of $2.30 billion, a P/E ratio of 31.39, a P/E/G ratio of 1.89 and a beta of 1.24. The firm’s 50-day moving average price is $55.04 and its two-hundred day moving average price is $47.81. Astrana Health, Inc. has a 52-week low of $32.04 and a 52-week high of $63.20. The company has a quick ratio of 1.84, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter last year, the business posted $0.47 EPS. As a group, sell-side analysts forecast that Astrana Health, Inc. will post 1.17 earnings per share for the current year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.